EBSEBSHealthcare · Drug Manufacturers - Specialty & Generic

EBS Stock Forecast: Emergent BioSolutions, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$5.50
−1.96% on the day

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. hold a median 12-month price target of $10 — +81.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$288.4M
Ticker Nerd rank
80/ 100
Median analyst target
$10
Analysts covering
3
Revenue$226.8M+74.1% y/y
Operating income$66.2M
Net income−$180.2M
Free cash flow$54.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.9%
1M
−13.8%
YTD
−55.5%
1Y
−45.7%
From 52W high
−60.4%
From 52W low
+23.6%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EBS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Emergent BioSolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
80/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
100
Value
99
Issuance
98
Quality
95
Size
60
Revisions
42
Momentum
26
Growth
21
Volatility
19

Accruals (100): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (19): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26EBSHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy0 Hold1 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +81.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$10
21 Aug 2026JP MorganReinstatesUnderweight—
10 Aug 2026HC Wainwright & Co.MaintainsBuy$12 → $10
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy$15 → $12
16 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—
7 Nov 2024BenchmarkMaintainsBuy—
13 Sept 2024Rodman & RenshawReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—
16 Aug 2024BenchmarkReiteratesBuy—
9 Aug 2024BenchmarkReiteratesBuy—
3 July 2024BenchmarkReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EBS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EBS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Emergent BioSolutions, Inc. returned −45.7% against +12.2% for the S&P 500, dividends included.

EBS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26EBSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−69.5%
Analysts raising
1
Analysts cutting
0
Fundamentals

Emergent BioSolutions, Inc. (EBS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.6×

Cheaper than 61% of US stocks

Price / sales
0.4×

Cheaper than 81% of US stocks

Price / book
0.9×

Cheaper than 71% of US stocks

EV / EBITDA
5.0×

Cheaper than 53% of US stocks

Growth & margins
Revenue growth (YoY)
−52.4%

Higher than 5% of US stocks

Earnings growth (YoY)
74.1%

Higher than 80% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
5.8%

Higher than 58% of US stocks

Net margin
−40.2%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−58.2%

Higher than 19% of US stocks

Return on assets
1.9%

Higher than 58% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Emergent BioSolutions, Inc. (EBS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Emergent BioSolutions, Inc. has a market value of $288.4M and an enterprise value of $626.4M.

  • Revenue in the twelve months to 30 June 2026: $742.3M. The latest quarter shrank 52.4% year on year.

  • Net income over the same four quarters: −$176.8M, a −23.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.55.

  • Free cash flow in the twelve months to 30 June 2026: $85.9M.

  • Emergent BioSolutions, Inc. spent $36.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 51.3M.

  • Trailing P/E: 8.6×; forward P/E: 5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Emergent BioSolutions, Inc. employs 900 people — $825K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

EBS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
EBSEmergent BioSolutions, Inc.$288.4M80
TLRYTilray Brands, Inc.$347.3M16
LFCRLifecore Biomedical, Inc.$242.2M2
BIOABioAge Labs, Inc.$226.3M16
SIGASIGA Technologies, Inc.$195.6M51
EOLSEvolus, Inc.$435.3M89
ADCTADC Therapeutics SA$189.9M86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Emergent BioSolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EBS news & analysis

Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference

Business Wire · 10 Nov 2026neutral

Emergent BioSolutions said senior management will participate in the Jefferies Global Healthcare Conference in London, November 16–19, 2026. The company’s webcast presentation is scheduled for November 18, with a replay expected to be available for approximately three months.

Why it matters — EBS watchers may note the scheduled opportunity to hear from the company’s senior management and access its presentation.

Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution

Seeking Alpha · 6 Nov 2026negative

Emergent BioSolutions lowered FY26 revenue and EBITDA guidance, citing government procurement delays and continued pricing pressure in the U.S. naloxone market. In 3Q26, adjusted EBITDA was a $4.6 million loss and net loss was $32.7 million, alongside sharply weaker gross margin and profitability.

Why it matters — The lowered outlook and quarterly losses underscore uncertainty around EBS’s commercial recovery despite progress on cost savings and debt reduction.

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Business Wire · 4 Nov 2026positive

Emergent BioSolutions received a modification exercising an option under an existing delivery order, valued at up to $22.3 million, to supply BioThrax to the U.S. Department of War. The first delivery, valued at approximately $7.4 million, will begin this year, with remaining deliveries expected in 2027.

Why it matters — The order modification adds a BioThrax supply commitment under Emergent's existing delivery order.

Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors

The Motley Fool · 3 Nov 2026neutral

Emergent BioSolutions updated its full-year revenue guidance to $600 million to $645 million. Restructuring actions are expected to generate $40 million in annualized savings.

Why it matters — The updated revenue range and anticipated savings are relevant to investors tracking EBS’s financial outlook and restructuring.

FAQ

Frequently asked questions about EBS stock

What is the EBS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EBS stock a buy right now?

Of the 3 analysts covering Emergent BioSolutions, Inc., 2 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Emergent BioSolutions, Inc. 80 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EBS?

As at 17 Nov 2026, Emergent BioSolutions, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).

Will EBS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +81.8% from the last close, and Ticker Nerd's factor model ranks Emergent BioSolutions, Inc. 80 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EBS stock forecast for 2030?

No analyst covering Emergent BioSolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has EBS stock performed over the past year?

Emergent BioSolutions, Inc. returned -45.7% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Emergent BioSolutions, Inc. do?

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats.

What is the latest news on EBS?

The most recent item we track (GlobeNewsWire, 16 Nov 2026): "Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola". Asimov and Emergent BioSolutions announced a cell line development partnership to advance novel antibodies against Ebola.

Company

About Emergent BioSolutions, Inc.

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government agencies, healthcare providers, and other institutional customers. The company’s portfolio includes commercial products, medical countermeasure products, and services, with an emphasis on areas such as opioid overdose reversal, smallpox and anthrax preparedness, and contract development and manufacturing support. Emergent BioSolutions plays a specialized role in the healthcare and biodefense markets by supplying products and services designed to support emergency readiness and public health response across the United States and international markets.

CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph. · 900 employees · United States · https://www.emergentbiosolutions.com